NewsNovo
has obtained the necessary regulatory clearances in Australia to move forward with its first-in-human study of EQ504, a development that sets the stage for the company's next step in clinical development.
The company announced on October 5, 2026, that it received approval from the Human Research Ethics Committee and clearance from the Therapeutic Goods Administration under the Clinical Trial Notification scheme.
Equillium expects to begin dosing healthy participants by early November 2026. The trial is a single-center investigation using a randomized, double-blinded, and placebo-controlled design.
Its primary goal is to assess how safe and tolerable EQ504 is, while also measuring how the drug behaves in the body and what biological changes it triggers.
Keep reading